# Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

> **NCT02055781** · PHASE3 · TERMINATED · sponsor: **CTI BioPharma** · enrollment: 311 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Best Available Therapy

## Key facts

- **NCT ID:** NCT02055781
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055781, "Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02055781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*